Please login to the form below

larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Bayer’s Vitrakvi (larotrectinib) was the first drug to reach the market for NTRK fusion cancers and also only the second to be approved by the FDA for a ‘tissue agnostic’

Latest news

Trulicity’s ascent lifts Lilly

Vitrakvi (larotrectinib).
EMA says Lilly’s Lartruvo should not be prescribed

larotrectinib) for NTRK gene fusion cancers.
Pfizer takeover rumour ignites Amarin shares

GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for
Lilly adds to pharma M&A run with $8bn Loxo buy-out

Loxo gained its first ever drug approval in late November with Vikrakvi (larotrectinib), now FDA approved to treat any solid tumour that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.
Orphan drugs dominate FDA's record-breaking year

Also worth a mention is Lox/Bayer’s Vitrakvi (larotrectinib), which became the second drug to be approved based on a biomarker across different types of tumours rather than the location

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... In Europe, a marketing application for
Cancer immunotherapy: What's on the horizon?

also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Account Director, Medical Education: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Director – Healthcare PR: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...